Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

Drug industry

Article Abstract:

Prices for drug stocks soared between Aug 1994 and Aug 1995, but the trend toward vertical and horizontal consolidation that is occurring in the industry will place a premium on investing in large multinational companies that offer a wide array of new medicines and have the wherewithal to fund research and development. Overall, drug stocks are no longer cheap and only a few have attractive rankings.

Author: Butler, Jeremy J., Markey, Keith A., Malhotra, Vik, Ferguson, Keith E., Rho, George I.H., Byrne, Andrew J.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1995
Pharmaceutical Preparation Manufacturing, Pharmaceutical Preparations, Drugs, Eli Lilly and Co., Pfizer Inc., Magna International Inc., Glaxo Wellcome PLC, Genentech Inc., SmithKline Beecham PLC, Warner-Lambert Co., Biogen Inc., Bristol-Myers Squibb Co., ALZA Corp., Chiron Corp., Forest Laboratories Inc., Genzyme Corp., Immunex Corp., IVAX Corp., Mylan Laboratories Inc., Perrigo Co., Schering-Plough Corp., AZA, AHP, BGEN, BMY, CHIR, CYGN, FRX, GENZ, ICN, IMNX, IVX, LLY, MLY, PRGO, PFE, SGP, WLA, Genetics Institute Inc., GENI, GNE, Valeant Pharmaceuticals International, Wyeth, Merck & Company Inc., MKC, Rhone-Poulenc Rorer Inc., Hoechst Marion Roussel Inc., Upjohn Co., Cygnus Therapeutic Systems, Roberts Pharmaceutical Corp., RPCX, R.P. Scherer Corp., RPR, Gensia Pharmaceuticals Inc., GNSA, SHR

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Myriad Genetics

Article Abstract:

The shares of Myriad Genetics, Inc. have wide price appreciation potential over the 2010-2012 timeframe. The Salt Lake City, Utah-based company develops tests to assess the risk of developing diseases and produces drugs for various diseases.

Author: Markey, Keith A.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007
Drugs, Biotechnology industry, Biotechnology industries, Myriad Genetics Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Amgen

Article Abstract:

The price appreciation potential of Amgen Inc. for the years 2010-2012 is discussed. The Thousand Oaks, California-based company develops and manufactures human therapeutic agents.

Author: Markey, Keith A.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry, Securities, Amgen Inc., AMGN, United States, Evaluation, Stocks, Stock prices, Company securities
Similar abstracts:
  • Abstracts: Trucking industry. part 3
  • Abstracts: Railroad industry. Gildan Activewear
  • Abstracts: Wireless networking industry. ViaSat, Inc
  • Abstracts: Applied Signal. eBay Inc. Medicis Pharm
  • Abstracts: DSP Group, Inc. Openwave Systems
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.